No files are available for download.
Tags
Funding
This research was made possible through the generous support of American Society of Hematology.
Creative Commons license
Except where otherwised noted, this item's license is described as a CC-BY 4.0 Attribution license.
Publisher
PEDSnet
Project Description
This study was intended to determine whether timely initiation of hydroxyurea (HU) prevents the development of early cerebrovascular changes in children with sickle cell disease (SCD). This project seeks to establish a link between early HU and cerebrovascular protection, promoting timely HU initiation, reducing the need for CRCT, and lowering stroke rates in children with SCD.
Study Aims
- Identify the impact of the 2014 NHLBI guidelines recommending early and universal HU on 1A) HU prescriptions and 1B) cerebrovascular outcomes in a national cohort of children and young adults born between 2009-2023. We hypothesize that the incidence of abnormal TCD and AIS has decreased since 2014, and that this occurred alongside an increase in HU prescriptions.
- Determine the relationship between timely HU initiation before 2 years of age and the occurrence of cerebrovascular disease in children and young adults with SCD. We hypothesize that timely HU initiation by 2 years of age leads to a lower risk of abnormal TCD or AIS.